Molecular pathology of schizophrenia: more than one disease process?
about
The impact of environmental factors in severe psychiatric disorders.Asenapine versus placebo for schizophreniaAsenapine versus placebo for schizophreniaChlorpromazine versus penfluridol for schizophreniaSelective noradrenaline reuptake inhibitors for schizophreniaCompeting definitions of schizophrenia: what can be learned from polydiagnostic studies?Sertindole in the management of schizophreniaAvolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research.The concept of psychosis: historical and phenomenological aspectsIdentifying unmet therapeutic domains in schizophrenia patients: the early contributions of Wayne Fenton from Chestnut LodgeTreating Negative Symptoms in Schizophrenia: an UpdateWhat does schizophrenia teach us about antipsychotics?Noradrenergic Modulation of Cognition in Health and Disease.The current conceptualization of negative symptoms in schizophreniaThe relationship of structural brain imaging parameters to antipsychotic treatment response: a review.The relevance to psychiatry of recent advances in functional imagingStructural and functional brain imaging in schizophrenia.Stability of CT scan findings in schizophrenia: results of an 8 year follow-up study.Negative symptoms in schizophrenia: avolition and Occam's razorDementia praecox to schizophrenia: the first 100 years.Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies.Reviewing the Dissociative Symptoms in Patients With Schizophreniaand their Association With Positive and Negative Symptoms.Cerebral white matter abnormalities and their associations with negative but not positive symptoms of schizophrenia.Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.Willed action and its impairments.The epidemiology of the genetic liability for schizophrenia.Csf amines and their metabolites in first episode drug naive schizophrenic patients and their correlations with dimensions of schizophrenia.A crossover study of clocapramine and haloperidol in chronic schizophrenia.Cognition in schizophrenia: Past, present, and future.Neurological soft signs, cognitive dysfunction and ventricular brain ration in schizophrenics.Subtyping schizophrenia: implications for genetic research.Functional brain mapping of psychopathology.Neuropsychology of reward learning and negative symptoms in schizophreniaDifferential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review.Symptom dimensions and outcome in schizophreniaPlasma nitrate levels in deficit versus non-deficit forms of schizophreniaThe diagnostic concept of schizophrenia: its history, evolution, and future prospects.Impairment of willed actions and use of advance information for movement preparation in schizophreniaAnalysis on evolution and research focus in psychiatry field.AIDS dementia-related psychosis: is there a window of vulnerability?
P2860
Q21129355-B62A6A39-2B3A-4D2C-A081-4F960B8FFD29Q24187012-891ED147-C44E-480B-8FB3-2F516350F45CQ24187667-2F25145A-1372-448C-9AAE-79A1358B54A1Q24188120-74E6BD90-039F-4F66-B3EA-7E8AE34C6B20Q24197825-CB95CA60-51EF-4CC4-91D6-A658DED6B628Q24616511-D1E80BD1-0FAA-4782-B252-D2F27B0ADC44Q24621369-FCCF29D7-B1BE-4486-A5C6-70325CFCC962Q24630535-3CBE6434-346E-483E-A383-1E90CB5D98F5Q24643705-59FE4201-86B4-4A56-B8B0-F83050C36D6FQ24644123-9C2A0079-C2D6-4851-9133-AB041CC10026Q26744805-2E16A5BE-829D-44C9-91C7-FC164F28B11AQ26823906-806382D4-DC6D-4580-9FDD-0612636DA9F2Q30354689-61CC583C-F3F4-45F7-878F-8DCEE3322A86Q30364829-BF358728-6941-4A31-AA52-527FD3C2C327Q30839573-01467070-7478-4BC7-BAD0-6832F7A6980EQ31007936-7856ACC8-987F-47A6-825B-7E8546FD437AQ33396727-97ED1C8D-1973-467D-AA53-4836CD4EF6E7Q33627313-9190E316-7293-4679-8514-EDD5166B9F1FQ33707635-8AB4C03B-997A-4796-B5B8-093E9EA9C902Q33739068-9B6ED77E-BDF2-4677-A03D-DEE781CA640DQ33833648-9D67C687-F743-46F4-A056-ADD638F9A487Q33834444-D8A50C43-A525-4FDA-9C25-E5CC78DF0B65Q33852998-CE315768-585D-4B69-B6E6-D716DF2B2567Q33921723-1E76F83A-14E1-40B5-A467-508AB47A4426Q34031259-AB29DD4F-83EE-44CA-AAA1-3B2377E7F776Q34113081-7FD1A782-61A3-4ABA-BFA2-D500EDE1945AQ34195991-C5D235FB-8868-4779-8379-DC6D7B4E0C39Q34201265-838224C6-9F96-4E4A-9A6C-AD3A707D83D8Q34224025-E07270E8-B9F1-4782-8347-CC4EE00BBCE0Q34250004-751488A5-8320-4C83-8728-4D7C5E784B0AQ34542103-09E01718-4A36-4023-9F04-BB26DB332B87Q34574575-0CD630B0-737F-4083-93EA-40ED755B2B23Q34620858-68E52D5C-4282-4BD4-B936-5DCDFA470C0AQ34744036-DB9EF085-5019-4387-9B40-FD70686261B9Q34884773-A3991754-E01B-4112-9FFC-5B6BB02F0239Q35162552-6E222E54-3960-4816-878A-88B2AD76AAE7Q35237275-C901FA34-72BC-472E-AA4E-07D72FC6469AQ35450581-8AD89B2E-8AA5-4162-B4BB-C3EC1B32F6B2Q35623530-1C24A584-417A-415D-A7B5-C6B694EFC468Q35664512-50AEBB3E-5945-4767-A7C8-D3F3C42FA7DE
P2860
Molecular pathology of schizophrenia: more than one disease process?
description
1980 nî lūn-bûn
@nan
1980 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1980 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1980年の論文
@ja
1980年論文
@yue
1980年論文
@zh-hant
1980年論文
@zh-hk
1980年論文
@zh-mo
1980年論文
@zh-tw
1980年论文
@wuu
name
Molecular pathology of schizophrenia: more than one disease process?
@ast
Molecular pathology of schizophrenia: more than one disease process?
@en
Molecular pathology of schizophrenia: more than one disease process?
@nl
type
label
Molecular pathology of schizophrenia: more than one disease process?
@ast
Molecular pathology of schizophrenia: more than one disease process?
@en
Molecular pathology of schizophrenia: more than one disease process?
@nl
prefLabel
Molecular pathology of schizophrenia: more than one disease process?
@ast
Molecular pathology of schizophrenia: more than one disease process?
@en
Molecular pathology of schizophrenia: more than one disease process?
@nl
P2860
P3181
P356
P1433
P1476
Molecular pathology of schizophrenia: more than one disease process?
@en
P2093
P2860
P3181
P356
10.1136/BMJ.280.6207.66
P407
P577
1980-01-12T00:00:00Z